keep
sachin
bindal
amit
koli*
ever
since
india
opened
patent
regime
january
include
product
ﬁeld
pharmaceutical
law
domain
kept
alive
interest
various
stakeholder
rightly
also
known
pharmacy
world
global
market
leader
export
generic
drug
united
state
japan
well
country
africa
europe
indian
industry
turnover
billion
registering
growth
rate
per
cent
stood
r
crore
one
largest
consumer
medicine
even
though
accessibility
across
economically
weaker
section
remains
issue
equipped
balance
quid-pro-quo
requirement
jurisprudence
still
evolving
recent
judicial
precedent
reafﬁrmed
ofﬁce
proposed
disclosure
international
nonproprietary
name
application
relating
pharmainventions
thereafter
organized
ceutical
meeting
different
discus
proposal
receive
feedback
feasibility
implementation
policy
make
mandatory
rule
amended
provide
necessary
basis
put
voiced
concern
ﬁnally
decided
reject
least
making
remain
unchanged
go
credit
speciﬁcation
removed
recently
issued
guideline
examination
however
instruct
examiner
search
prior
art
based
disclosed
case
second
medical
use
invention
author
koli
associate
partner
gurgaon
attempt
explore
tool
searching
whether
would
indeed
thing
simpler
directed
ask
applicant
disclose
substance
claimed
event
give
information
upon
request
required
seek
ascertain
examine
discussed
held
dropped
general
background
ofﬁcial
given
designated
health
organization
identiﬁes
active
ingredient
unique
globally
recognized
email
thank
dr
deepa
kachroo
tiku
providing
unconditional
guidance
critical
comment
without
paper
could
written
fullest
view
expressed
solely
alone
way
represent
aiswariya
chidambaram
insight
snapshot
july
available
frostcomsublibdisplay-market-insight-topdoid=
may
business
ministry
external
affair
government
investment
technology
promotion
division
industryserviceslanding
june
controller
design
trade
mark
field
october
para
new
therapeutic
us
published
oxford
university
press
right
reserved
table
understanding
indication
n-hydroxyphenylethanamide
paracetamol
anti-pyretic
-acetoxybenzoic
acid
aspirin
analgesic
antipyretic
anti-inﬂammatory
easy
remember
unlike
union
pure
applied
chemistry
nomenclature
apart
system
british
approved
adopted
identify
provides
example
question
using
raised
number
including
following
suddenly
sought-after
beneﬁcial
regarding
might
extra
burden
seeking
vested
group
agency
fueling
sudden
need
related
method
synthesis
string
type
jurisdiction
result
title
acetoxybenzoic
cooperation
treaty
composition
rotigotine
rotigotina
thiophen
tetrahydronaphthalen
thienyl
tetrahydro
naphthalenol
claim
exclamation
wildcard
represents
zero
unlimited
character
earlier
premise
help
conduct
effectively
hypothesis
designed
sample
shown
found
used
two
relevant
four
document
fact
appeared
missed
common
thus
prove
effective
instance
conﬁrm
provisional
conclusion
another
study
treatment
parkinson
disease
restless
leg
syndrome
trial
changed
subject
matter
molecule
broaden
presumption
old
nevertheless
miss
generally
reached
mentioned
captured
three
belong
family
discloses
comprising
addition
salt
remaining
talk
novel
word
whointmedicinesservicesinninnquidanceen
april
ﬁnds
term
appear
within
n-number
conducted
total
database
december
wn
operator
polymorph
axitinib
pyridin
indazol
sulfanyl
highly
already
among
listed
orange
book
book-listed
food
administration
approval
fail
efﬁcient
obtain
crystalline
form
disclosing
corresponding
currently
molecular
formula
structural
diagram
clinical
code
systematic
chemical
abstract
service
registry
etc
tried
tested
well-established
worldwide
ing
data
major
requires
sometimes
conﬂict
referred
national
de´nominations
commune
francaises
japanese
similar
purpose
difference
flurothyl
whereas
flurotyl
lead
confusion
concluded
create
prosecution
link
good
idea
take
linking
unnecessarily
cumbersome
ﬁling
best
responsibility
regulatory
body
stage
time
ﬁled
soon
research
development
show
promise
accordingly
compound
unlikely
patenting
actually
laboratory
acronym
naming
therefore
practical
challenge
almost
never
besides
allow
adding
inclusion
present
viable
approach
internationally
done
applying
linkage
meant
prevent
infringement
followed
several
member
closer
collaboration
regulator
website
repository
exercise
kyoto
bioinformatics
center
obtained
presented
performed
acting
dopamine
agonist
indicated
expiry
november
march
september
submitted
sponsorapplicant
depending
status
publishes
list
mapped
year
back
decree
gazette
federal
mexico
regulation
industrial
property
amendment
imposed
mexican
institute
obligation
publish
special
listing
allopathic
brought
beneﬁt
owner
authority
grant
registration
covering
marketing
inform
holder
licensee
existing
licence
must
declaration
infringe
work
determine
pending
indicates
valid
infringed
opportunity
demonstrate
alternative
similarly
china
maintains
separate
track
compoundcomposition
check
certify
acknowledge
liability
damage
resulting
future
ﬁnding
frequent
inspection
order
avoid
copying
patented
justiﬁed
aim
professional
universally
existence
identiﬁcation
safe
prescription
dispensing
patient
communication
exchange
role
mainly
commercial
reader
recall
bayer
cipla
high
court
supreme
clearly
ruled
overlap
apply
context
equivalence
evaluation
engine
docsqueryaicfm
report
joint
commission
commerce
device
subgroup
task
force
august
beijing
sa´nchez
reform
introduced
managing
intellectual
no
delhi
judgement
pronounced
appeal
civil
disposed
finston
consulting
serial
almotriptan
hit
dimethylaminoethyl
indol
pyrrolidin
alvimopan
ibrutinib
hydroxyphenyl
dimethylpiperidin
methyl
phenylpropanoyl
phenoxyphenyl
pyrazolo
pyrimidin
piperidin
bortezomib
pyrazin
phenylalanin
leucin
boronic
crizotinib
dichloro
ﬂuoro
pyrazol
prasugrel
cyclopropyl
tetrahydrothieno
levomilnacipran
diethyl
phenyl
cyclopropan
carboxamid
allocated
advice
expert
advisory
panel
pharmacopoeia
preparation
process
selection
follows
main
step
requestapplication
made
company
review
selected
time-period
objection
lapsed
recommended
importantly
speciﬁcally
human
substantial
regard
description
risk
losing
novelty
due
delay
obtaining
lack
clarity
consequence
mandate
possible
loss
decides
withhold
want
misuse
third
party
frivolous
opposition
invalidation
proceeding
particularly
ground
act
difﬁculties
specifying
component
markush
representation
deﬁnes
shall
contain
performing
applicantinventor
entitled
protection
reliable
source
describing
aid
enabling
person
skilled
carry
wise
imposes
overcome
important
legal
barrier
legally
speaking
agreement
trade-related
aspect
said
cannot
discriminate
ﬁelds
rejecting
saved
potentially
accused
discrimin
herein
symbol
indicate
collection
structure
commonly
text
ation
contrary
careful
thought
require
came
surprise
pharma
debate
longer
restricted
evokes
serious
emotive
certainly
faced
dilemma
address
admirably
took
reasonable
balanced
pursuant
elaborate
discussion
augur
fraternity
thoroughly
usefulness
great
impact
initiating
nationwide
outlined
drawn
ie